Last week, we told you that Pfizer’s acquisition of Wyeth had been completed, which enhanced the line of products offered by Pfizer Animal Health. Read “New Pfizer Animal Health unveiled” and “Pfizer: Benefits synergistic and even serendipitous.”
Wyeth, acquired by Pfizer, had been the parent company of Fort Dodge Animal Health.
This week, Boehringer Ingelheim Vetmedica, Inc. (BIVI) announced that it had closed its deal with Pfizer to acquire certain Fort Dodge Animal Health vaccines, parasiticides and antibiotics for the BIVI cattle business in the United States and Canada.
The Fort Dodge products acquired by BIVI include the well-established vaccine brands Triangle®, Pyramid®, Presponse® and TrichGuard®; Cydectin® brand parasiticide; the ToDAY® and ToMORROW® pharmaceutical products for the dairy industry; and the Polyflex® antibiotic.
According to Colin Meyers, executive director of BIVI’s cattle business, the addition of these brands to the company’s cattle product line provide producers with a broader range of health solutions from a single source. “These products are strong, well-established brands that are highly regarded and utilized by veterinarians and beef and dairy cattle producers,” Meyers explains. “The Fort Dodge products are complementary to our existing BIVI cattle product portfolio and we look forward to continue to provide them to the U.S. and Canadian markets.”
As part of the cattle product acquisition, BIVI also is acquiring Fort Dodge manufacturing and other assets, and will continue its industry-leading research and product development efforts to bring additional health solutions to cattle producers.
“We know that maintaining herd health is essential to the bottom line of beef and dairy producers and the veterinarians who serve them,” Meyers adds. “Through this acquisition and our other ongoing efforts, we are committed to providing the highest-quality, most-effective products available.”